

PUBLIC SUMMARY DOCUMENT

Product: Hollister High Output Collection Bag

Applicant: Hollister

Date of SPAP Meeting: 20 October 2020

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the High Output Collection Bag in subgroup 11(a) of the Stoma Appliance Scheme (SAS) Schedule. The product was proposed for listing at the unit price of \$14.404, with a maximum monthly quantity of 20 units.

2. Comparator

The applicant nominated Coloplast Mio High Output and Fistula Collection Bag (SAS Code 5700B) as the comparator. This product is currently listed in subgroup 11(a) of the SAS Schedule at the unit price of \$14.404 with a maximum monthly quantity of 20 units. This was accepted by the Stoma Product Assessment Panel (SPAP) as an appropriate comparator

3. Background

This was the SPAP's first consideration of this product.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a high output collection bag.

5. SPAP Comment

Clinical Analysis

The Panel noted that many of the current High Output pouches available on the SAS Schedule connect to a standard collection bag that utilises a 'stepped connector'. The Panel noted that the proposed product connects to the Moderma Flex Soft Convex High Output.

The Panel agreed the proposed product provides an alternative to what is currently listed in subgroup 11(a) of the SAS Schedule.

Economic Analysis

Not undertaken.

Financial Analysis

The requested price is the same as the accepted comparator. It is therefore, unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

6. SPAP Recommendation

The SPAP recommended that the High Output Collection Bag, be listed in subgroup 11(a) of the SAS Schedule at the unit price of \$14.404, with a maximum monthly quantity of 20 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

Hollister accepts the outcome as noted above by SPAP.